Sunil Pancholi
Overview
Explore the profile of Sunil Pancholi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soosainathan A, Iravani M, El-Botty R, Alexander J, Sourd L, Morisset L, et al.
Cancer Res
. 2023 Oct;
84(1):17-25.
PMID: 37801608
Significance: Targeting transcription-associated CDK9 synergizes with CDK4/6 inhibitor to drive tumor regression in multiple models of endocrine- and palbociclib-resistant ER+ breast cancer, which could address the challenge of overcoming resistance...
2.
Pancholi S, Simigdala N, Ribas R, Schuster E, Leal M, Nikitorowicz-Buniak J, et al.
NPJ Breast Cancer
. 2022 Nov;
8(1):125.
PMID: 36446866
The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable...
3.
Peck B, Bland P, Mavrommati I, Muirhead G, Cottom H, Wai P, et al.
Cancer Res
. 2021 Jan;
81(4):847-859.
PMID: 33509944
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies for this...
4.
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, et al.
Nat Commun
. 2020 Aug;
11(1):4053.
PMID: 32792481
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing...
5.
Pancholi S, Ribas R, Simigdala N, Schuster E, Nikitorowicz-Buniak J, Ressa A, et al.
Oncogene
. 2020 Apr;
39(25):4781-4797.
PMID: 32307447
Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than...
6.
Pancholi S, Leal M, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, et al.
Breast Cancer Res
. 2020 Feb;
22(1):14.
PMID: 32005287
After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni.
7.
Pancholi S, Leal M, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, et al.
Breast Cancer Res
. 2019 Dec;
21(1):135.
PMID: 31801615
Background: Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated...
8.
Franken A, Honisch E, Reinhardt F, Meier-Stiegen F, Yang L, Jaschinski S, et al.
J Mol Diagn
. 2019 Nov;
22(1):111-121.
PMID: 31669227
Mutations in the ligand-binding domain (LBD) of the ESR1 gene result in resistance to estrogen deprivation therapy (EDT) in breast cancer. Their detection might enable optimization of therapy strategies. However,...
9.
Cocce K, Jasper J, Desautels T, Everett L, Wardell S, Westerling T, et al.
Cell Rep
. 2019 Oct;
29(4):889-903.e10.
PMID: 31644911
Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that...
10.
Sava G, Fan H, Fisher R, Lusvarghi S, Pancholi S, Ambudkar S, et al.
Oncogene
. 2019 Sep;
39(3):651-663.
PMID: 31530935
The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may...